First-Line Anti-Egfr Agents (panitumumab or Cetuximab) Plus Chemotherapy in Patients With Metastatic Colorectal Cancer: Onco-Colon Turkey Study Subgroup Analysis

Isikdogan, A.Turk, H.Bilir, C.Sendur, M.Karabulut, B.Artac, M.Cicin, I.2023-06-162023-06-1620220923-75341569-8041https://doi.org/10.1016/j.annonc.2022.04.180https://hdl.handle.net/20.500.14365/1059ESMO 24th World Congress on Gastrointestinal Cancer -- JUN 29-JUL 02, 2022 -- Barcelona, SPAIN[Abstract Not Available]eninfo:eu-repo/semantics/openAccessFirst-Line Anti-Egfr Agents (panitumumab or Cetuximab) Plus Chemotherapy in Patients With Metastatic Colorectal Cancer: Onco-Colon Turkey Study Subgroup AnalysisConference Object10.1016/j.annonc.2022.04.180